NZ238360A - 2,4-diamino- and 4-amino-2-(n-morpholinyl)-5-(3,5-dichlorophenyl)-6- trifluoromethyl pyrimidine - Google Patents

2,4-diamino- and 4-amino-2-(n-morpholinyl)-5-(3,5-dichlorophenyl)-6- trifluoromethyl pyrimidine

Info

Publication number
NZ238360A
NZ238360A NZ238360A NZ23836091A NZ238360A NZ 238360 A NZ238360 A NZ 238360A NZ 238360 A NZ238360 A NZ 238360A NZ 23836091 A NZ23836091 A NZ 23836091A NZ 238360 A NZ238360 A NZ 238360A
Authority
NZ
New Zealand
Prior art keywords
compound
pharmaceutically acceptable
salt
compound according
acceptable salt
Prior art date
Application number
NZ238360A
Other languages
English (en)
Inventor
Michael John Leach
Malcolm Stuart Nobbs
Ramachandran Iyer
Clive Leonard Yeates
Philip Alan Skone
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Priority to NZ248501A priority Critical patent/NZ248501A/en
Priority to NZ272001A priority patent/NZ272001A/en
Publication of NZ238360A publication Critical patent/NZ238360A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Paper (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NZ238360A 1990-06-01 1991-05-31 2,4-diamino- and 4-amino-2-(n-morpholinyl)-5-(3,5-dichlorophenyl)-6- trifluoromethyl pyrimidine NZ238360A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NZ248501A NZ248501A (en) 1990-06-01 1991-05-31 4-amino-2-(4-n-propylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidine
NZ272001A NZ272001A (en) 1990-06-01 1991-05-31 Substituted 5-(phenyl)-pyrimidine derivatives and medicaments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909012316A GB9012316D0 (en) 1990-06-01 1990-06-01 Pharmacologically active cns compounds

Publications (1)

Publication Number Publication Date
NZ238360A true NZ238360A (en) 1997-03-24

Family

ID=10676964

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ238360A NZ238360A (en) 1990-06-01 1991-05-31 2,4-diamino- and 4-amino-2-(n-morpholinyl)-5-(3,5-dichlorophenyl)-6- trifluoromethyl pyrimidine
NZ272001A NZ272001A (en) 1990-06-01 1991-05-31 Substituted 5-(phenyl)-pyrimidine derivatives and medicaments
NZ248501A NZ248501A (en) 1990-06-01 1991-05-31 4-amino-2-(4-n-propylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidine

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ272001A NZ272001A (en) 1990-06-01 1991-05-31 Substituted 5-(phenyl)-pyrimidine derivatives and medicaments
NZ248501A NZ248501A (en) 1990-06-01 1991-05-31 4-amino-2-(4-n-propylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidine

Country Status (25)

Country Link
EP (2) EP0679645A1 (enExample)
JP (1) JPH06340634A (enExample)
KR (1) KR920000733A (enExample)
AT (1) ATE141263T1 (enExample)
AU (2) AU652753B2 (enExample)
CA (1) CA2043640A1 (enExample)
CZ (1) CZ281070B6 (enExample)
DE (1) DE69121317T2 (enExample)
DK (1) DK0459819T3 (enExample)
ES (1) ES2093078T3 (enExample)
FI (1) FI912623A7 (enExample)
GB (1) GB9012316D0 (enExample)
GR (1) GR3021237T3 (enExample)
HU (2) HUT58707A (enExample)
IE (1) IE911861A1 (enExample)
IL (2) IL113599A (enExample)
MY (2) MY109958A (enExample)
NO (1) NO180375C (enExample)
NZ (3) NZ238360A (enExample)
PL (2) PL170373B1 (enExample)
PT (1) PT97827B (enExample)
RU (1) RU2091374C1 (enExample)
SK (1) SK278444B6 (enExample)
TW (1) TW224460B (enExample)
ZA (1) ZA914165B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
CH685978A5 (fr) * 1991-01-30 1995-11-30 Wellcome Found Comprimes dispersables dans l'eau.
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
JPH08504798A (ja) * 1992-12-18 1996-05-21 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体
GB9226377D0 (en) * 1992-12-18 1993-02-10 Babbedge Rachel C Pharmaceutical compositions
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9319341D0 (en) * 1993-09-17 1993-11-03 Wellcome Found Novel process
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
MY123528A (en) 1999-09-16 2006-05-31 Mitsubihsi Tanabe Pharma Corp Aromatic nitrogen-containing 6-membered cyclic compounds.
WO2001062233A2 (en) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
MXPA02010693A (es) 2000-04-28 2003-03-10 Tanabe Seiyaku Co Compuestos ciclicos.
WO2002008205A1 (en) * 2000-07-24 2002-01-31 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
MXPA03007623A (es) 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
PL372390A1 (en) * 2002-02-05 2005-07-25 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
EP1902028A2 (en) 2005-07-04 2008-03-26 Novo Nordisk A/S Histamine h3 receptor antagonists
CA2653062A1 (en) 2006-05-23 2007-11-29 Transtech Pharma, Inc. 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
ATE538116T1 (de) 2006-05-29 2012-01-15 High Point Pharmaceuticals Llc 3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2015107493A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
CA3023216A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
RU2769132C2 (ru) 2017-01-10 2022-03-28 Новартис Аг Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE518622A (enExample) *
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds

Also Published As

Publication number Publication date
NO180375C (no) 1997-04-09
PT97827B (pt) 1998-10-30
FI912623A0 (fi) 1991-05-31
HUT58707A (en) 1992-03-30
MY109958A (en) 1997-10-31
NZ248501A (en) 1997-03-24
IL113599A0 (en) 1995-08-31
DE69121317D1 (de) 1996-09-19
NO912100D0 (no) 1991-05-31
EP0459819B1 (en) 1996-08-14
HU211649A9 (en) 1995-12-28
PL170373B1 (pl) 1996-12-31
IE911861A1 (en) 1991-12-04
EP0679645A1 (en) 1995-11-02
PL166656B1 (pl) 1995-06-30
CZ281070B6 (cs) 1996-06-12
AU7809791A (en) 1991-12-05
JPH06340634A (ja) 1994-12-13
ZA914165B (en) 1993-03-01
KR920000733A (ko) 1992-01-29
SK278444B6 (en) 1997-05-07
ATE141263T1 (de) 1996-08-15
CS164391A3 (en) 1992-02-19
EP0459819A3 (en) 1992-03-11
RU2091374C1 (ru) 1997-09-27
AU680252B2 (en) 1997-07-24
HU911826D0 (en) 1991-12-30
IL98330A0 (en) 1992-06-21
NZ272001A (en) 1997-03-24
CA2043640A1 (en) 1991-12-02
AU6745594A (en) 1994-09-15
AU652753B2 (en) 1994-09-08
DE69121317T2 (de) 1997-01-02
EP0459819A2 (en) 1991-12-04
DK0459819T3 (da) 1996-09-02
MY136248A (en) 2008-08-29
NO912100L (no) 1991-12-02
PT97827A (pt) 1992-03-31
TW224460B (enExample) 1994-06-01
IL113599A (en) 1997-09-30
NO180375B (no) 1996-12-30
GR3021237T3 (en) 1997-01-31
GB9012316D0 (en) 1990-07-18
ES2093078T3 (es) 1996-12-16
FI912623A7 (fi) 1991-12-02
IL98330A (en) 1996-10-31

Similar Documents

Publication Publication Date Title
NZ238360A (en) 2,4-diamino- and 4-amino-2-(n-morpholinyl)-5-(3,5-dichlorophenyl)-6- trifluoromethyl pyrimidine
AP164A (en) Pharmacologically active cns compounds
US5136080A (en) Nitrile compounds
IE911859A1 (en) Pharmacologically active cns compounds
US6274588B1 (en) 4-phenyl-pyrimidine derivatives
AU2002227921B2 (en) Pyrimidine derivatives
HK1003928A (en) Substitutd phenylpyrimidine derivatives, useful in the treatment of prevention of cns disorders